We’d love to hear your feedback on this activity. It helps us to continually improve our products.
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Digestive Health Month took place over May 2023 to raise awareness of digestive diseases and cancers, which often remain overlooked in terms of policy, funding and research in Europe. We were delighted to talk with UEG’s Vice President Prof. Matthias Löhr (Karolinska Institutet, Stockholm, Sweden) around the public health and economic burden of digestive diseases, […]
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Ustekinumab is a human interleukin-12 and -23 antagonist approved for the treatment of Crohn’s disease. touchIMMUNOLOGY were delighted to talk with Dr. Lorenzo Bertani (University of Pisa, Pisa, Italy) to discuss the rationale, methodology and findings from his study investiagting whether baseline IL-23 serum levels could predict therapeutic response to ustekinumab. The abstract entitled ‘BASELINE […]
The LADI clinical trial (NCT03172377) aimed to demonstrate non-inferiority and cost-effectiveness of extending the adalimumab dosing interval in patients with Crohn’s disease in stable remission, when compared to standard dosing. We caught up with Reinier van Linschoten (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) to discuss the aims, design, eligibility criteria and […]
Crohn’s disease is a type of inflammatory bowel disease, where the gastrointestinal tract becomes inflamed, which results in symptoms such as diarrhoea, stomach aches and fatigue. We were delighted to speak with Reinier van Linschoten (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) around the health burden of Crohn’s disease, the disadvantages of […]
Vedolizumab has shown promise for achieving mucosal healing in patients with inflammatory bowel disease, the EARNEST trial shows. In this touchIMMUNOLOGY interview, we speak with Dr Vipul Jairath (Western University, University Hospital, London, ON, Canada) to discuss the importance of mucosal healing in inflammatory bowel disease as well as the findings and clinical implications of […]
The REACT-2 trial compared the effectiveness of two treatment algorithms, enhanced care or step-care, to reduce the risk of Crohn’s disease related complications at 2 years. In this touchIMMUNOLOGY interview, we speak with Dr Vipul Jairath (Western University, University Hospital, London, ON, Canada) to discuss the REACT-2 trial and future studies. The abstract entitled ‘A […]
The treatment plan for Crohn’s disease now focuses on a treat-to-target approach where effectiveness is determined using specific treatment goals, particularly mucosal healing on endoscopy. In this touchIMMUNOLOGY interview, we speak with Dr Vipul Jairath (Western University, University Hospital, London, ON, Canada) to discuss the treat-to-target approach in Crohn’s disease and the unmet needs in […]
Get the latest clinical insights from touchIMMUNOLOGY